Inventor · disambiguated record
Etienne Baulieu
Also filed as: BAULIEU ETIENNE · BAULIEU ETIENNE E · BAULIEU ETIENNE-EMILE
9 granted patents·10 pending applications·38 citations·filing 2001–2021
84Inventor score
Files withMAPREG6INST NAT SANTE RECH MED3BAULIEU ETIENNE2INST NAT DE LA SANTE ET DE LA RECH MEDICALE (INSERM)2BAULIEU ETIENNE E1
Top patents by PatentIndex Score
19 records- 0186US9339508B2Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injuryMAPREG·Filed 2012·Granted May 17, 2016·8 cites·6 claims
- 0283US8034798B2Use of 3-methoxy-pregnenolone in the production of a medicament for treating neurodegenerative diseasesMAPREG·Filed 2004·Granted Oct 11, 2011·23 cites·5 claims
- 0378US8334278B2Use of 3-methoxy-pregnenolone for the preparation of a drug for treating depressive disorders and long-term neurological diseasesBAULIEU ETIENNE-EMILE·Filed 2008·Granted Dec 18, 2012·4 cites·4 claims
- 0476US9518995B2FKBP52-Tau interaction as a novel therapeutical target for treating the neurological disorders involving Tau dysfunctionINST NAT DE LA SANTE ET DE LA RECH MEDICALE (INSERM)·Filed 2015·Granted Dec 13, 2016·2 cites·5 claims
- 0572US9943528B2Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of treatment-resistant depressionMAPREG·Filed 2017·Granted Apr 17, 2018·1 cites·3 claims
- 0667US2020138951A1Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunctionINST NAT SANTE RECH MED·Filed 2020·Application pending·0 cites
- 0758US2018161432A1Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunctionINST NAT SANTE RECH MED·Filed 2018·Application pending·0 cites
- 0856US9128104B2FKBP52-Tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunctionBAULIEU ETIENNE·Filed 2013·Granted Sep 8, 2015·0 cites·10 claims
- 0956US2005197322A1Compounds capable of binding to proteins constituting or associated with cytoskeletal elements, and their applications for the manufacture of medicamentsINST NAT SANTE RECH MED·Filed 2005·Application pending·0 cites
- 1054US2017056500A1FKBP52-Tau Interaction as a Novel Therapeutical Target for Treating the Neurological Disorders Involving Tau DysfunctionINST NAT DE LA SANTE ET DE LA RECH MEDICALE (INSERM)·Filed 2016·Application pending·0 cites
- 1152US2021322443A1Non-bioconvertible c3-substituted pregnenolone derivatives for use in the treatment of substance use disordersMAPREG·Filed 2021·Application pending·0 cites
- 1251US10561671B2Method for treating a degenerative disease of the nervous system using 3-methoxy-pregnenolone or derivatives thereofMAPREG·Filed 2015·Granted Feb 18, 2020·0 cites·8 claims
- 1350US11077122B2Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of substance use disordersMAPREG·Filed 2016·Granted Aug 3, 2021·0 cites·5 claims
- 1449US8648044B2FKBP52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunctionBAULIEU ETIENNE·Filed 2010·Granted Feb 11, 2014·0 cites·7 claims
- 1547US2003125311A1Compounds capable of binding with the cytoskeletonFiled 2001·Application pending·0 cites
- 1646US2007232575A1Treatment of Pulmonary Artery Hypertension with Dhea, Dheas, Dhea Analogs, or Dhea DerivativesBAULIEU ETIENNE E·Filed 2005·Application pending·0 cites
- 1737US2003059451A1Use of orally administered dehydroepiandrosterone, precursors and derivatives thereof in order to improve the papery aspect of the skinFiled 2001·Application pending·0 cites
- 1830US2003083323A1Oral use of dehydroepiandrosterone and some of its derivatives as pigmentation regulatorsFiled 2001·Application pending·0 cites
- 1930US2003050293A1Use of dehydroepiandrosterone, its precursors and derivatives, by oral administration, as hydrating agents with direct actionFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Etienne Baulieu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →